Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) Stock Price Today
Aura AI Summary
Key Stats
- $10.09BMarket Cap
- -Volume
- HealthSector
- $390.3452W High
- $241.7152W Low
- -Typical Hold Time
- $9.84BEnterprise Value
- -Div Yield
- -Trading Activity
Track Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Bio-Rad Laboratories, Inc. Class A Common Stock has traded between a low of $241.71 and a high of $390.34, highlighting its annual price range. Buy and sell Bio-Rad Laboratories, Inc. Class A Common Stock shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Most Recent News
Norwegian Cruise shares drop 3% as rising oil prices hurt fuel-cost outlook
Shares of Norwegian Cruise Line fell 3% due to rising oil prices, which increase fuel costs and pressure profit margins. Carnival and Royal Caribbean stocks also declined but less sharply, as Norwegian's higher debt and smaller scale make it more vul...
GE Aerospace's $12B acquisition of Consolidated Precision Products boosts defense supply chain and stock outlook.
GE Aerospace is acquiring Consolidated Precision Products for nearly $12 billion to bring its jet engine castings supply in-house, addressing a key manufacturing bottleneck. This move strengthens GE's defense segment, which showed strong revenue grow...
UiPath shares drop 3% despite Citi's Buy rating and $23 target amid mixed investor sentiment.
UiPath shares fell 3% to $13.55 even after Citi initiated coverage with a Buy rating and a $23 price target, citing UiPath's role in AI orchestration. The decline follows a third-quarter revenue guide below expectations, causing investor caution desp...
People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.